Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 3.71
- Piotroski Score 2.00
- Grade Sector Perform
- Symbol (FULC)
- Company Fulcrum Therapeutics, Inc.
- Price $3.04
- Changes Percentage (1%)
- Change $0.03
- Day Low $2.93
- Day High $3.10
- Year High $13.70
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $23.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.61
- Trailing P/E Ratio -5.15
- Forward P/E Ratio -5.15
- P/E Growth -5.15
- Net Income $-97,335,000
Income Statement
Quarterly
Annual
Latest News of FULC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Fulcrum Therapeutics Inc (FULC) Q3 2024 Earnings Call Highlights: Strategic Advancements Amidst ...
Fulcrum Therapeutics plans to keep its new assets wholly-owned for now, focusing on inherited aplastic anemias. The company received positive feedback from the FDA for healthy volunteer studies on poc...
By Yahoo! Finance | 4 days ago -
Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
Cash runway guidance indicates funding to cover operations until 2027. Discussions covered FDA validation of metrics, trial delays, and value proposition for losmapimod. The company is confident in ac...
By Yahoo! Finance | 1 month ago -
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
BofA Securities upgraded Fulcrum Therapeutics ahead of phase 3 losmapimod readout for FSHD, a rare genetic muscle disease. The company's new study using the "reachable workspace" endpoint has sparked ...
By Yahoo! Finance | 2 months ago
